the style assignment is described in one file
Article Assignment The news article you will write is based on a scientific article that your professor will assign to you. Each student will read the research article and write a news article about it. Students will work with their lab partner, functioning as peer editors. For example: 1) John and Maria are lab partners in the Cell biology course. 2) John was assigned a scientific paper related to a dialysis drug replacement 2) Maria was assigned a scientific article about a drug to prevent dementia. 3) John and Maria write the news article based on the scientific paper each one was assigned. 4) John emails Maria his scientific paper related to a dialysis drug replacement AND the news article he wrote about it. 4) Maria emails John her scientific paper about a drug to prevent dementia AND the news article she wrote about it. 5) John reads the dementia paper AND Maria’s news article. 5) Maria reads the dialysis paper AND John’s news article. 6) John proofreads, make suggestions and edits Maria’s news article based on the “Article Assignment Rubric”. All the changes John did to Maria’s news article were done utilizing the track changes feature of Microsoft Word. 6) Maria proofreads, make suggestions and edits John’s paper based on the “Article Assignment Rubric”. All the changes Maria did to John’s news article were done utilizing the track changes feature of Microsoft Word. Rubric 1) Deadlines (30pts total) a) Monday, October 25: Author sends draft to peer-editor (via email with copy to professor) and in Moodle (10pts) b) Monday, November 8: Editor sends revised version of news article to author and peer editor document (via email with copy to professor) and in Moodle (10 points) c) Monday, November 22: Author submits final version of news article via Moodle. (10pts) ***Late Moodle and email submission penalty: 24 hours: loose 5 points 48 hours: loose 10 points No exceptions. You have two weeks to complete each part of the assignment*** 2) Format (6pts total) a) Font: Arial, size 11 (2pts) b) Single space (2pts) c) 1’’ margins in the page (2pts) 3) Create a “catching” title for your news article (3pts total) a) Your title should be 8-10 words (2pts) b) Make three #hashtags for your article (1pts) Example of Title and hashtags: Scientists discover a new promising target for diabetes research #diabetes #betacells #insulin 4) News Highlight: a) Write the highlights of the article (5 points total) i) What was the drug discovered (1pts) ii) Where was it discovered (1pts) iii) General description of how the drug works (1pts) iv) How it might prevent, treat, or cure the disease (1pts) v) No less than 85 or more than 90 words (1pts) Example of News Highlight: Researchers have discovered a novel and druggable insulin inhibitory receptor, named inceptor. The latest study from Helmholtz Zentrum Muenchen, the Technical University of Munich and the German Center for Diabetes Research is a significant milestone for diabetes research as the scientific community celebrates 100 years of insulin and 50 years of insulin receptor discovery. The blocking of inceptor function leads to an increased sensitization of the insulin signaling pathway in pancreatic beta cells. This might allow protection and regeneration of beta cells for diabetes remission. 5) Article: a) First Paragraph: Introduction (12 points total) i) What is the disease and what it causes (2pts) ii) Why is important to find a treatment or cure to this disease (examples: disease complications, morbidity, mortality) (4pts) iii) What drug/drugs is/are available now for this disease and why it/they are not the ideal drug to target the disease. (4pts) iv) No less than 100 or more than 125 words (2pts) Example of Introduction: Diabetes mellitus is a complex disease characterized by the loss or dysfunction of insulin-producing beta cells in the islets of Langerhans, a specialist "micro-organ" in the pancreas that controls systemic blood sugar levels. Diabetes complications, such as chronic high blood sugar, systemic metabolic failure and, in the long-term, multi-organ damage, create enormous medical and social burdens and leads to premature death. Currently no pharmacological treatment can stop or reverse disease progression. Previous studies have demonstrated that intensive insulin therapy has the potential for improved blood sugar control and diabetes remission but also leads to unintended weight gain and even more severe side effects, such as an increased risk of deep drop in blood sugar causing unawareness. b) Second, Third, and Fourth Paragraphs: Article Body (28 points total) i) Describe the research focus of the senior author (2pts) ii) What are the hypothesis of the senior author related to the drug discovered by his research team (2pts) iii) Why the new drug is better than the existing drugs available (2pts) iv) Where was the study published and when (2pts) v) What were they key findings from their experiments? (4pts) vi) What was the experimental model? (Model organisms, cell, or tissue samples from patients?) (4pts) vii) What is the mechanism of the drug? (At the cellular or molecular level, how does the drug works?) (4pts) viii) What are the future goals of this study? (3pts) ix) No less than 350 or more than 400 words for the article body section (3pts) Example of Article Body: Heiko Lickert's* research focuses on the development of regenerative approaches to treat diabetes complementary and alternative to the classical immunological and metabolic therapies. "Insulin resistance in pancreatic beta cells causes diabetes. Therapies that sensitize those cells to insulin may protect patients with diabetes against beta cell loss and failure," says Lickert. With the discovery of the insulin inhibitory receptor, his research group has found a promising molecular target for beta cell protection and regeneration therapy that does not carry the unintended side effects of intensive insulin therapy. The findings of this remarkable study were published in January of this year in the prestigious scientific journal Nature. In experiments with mice, the researchers showed that the function of inceptor is to shield the insulin-producing beta cells from constitutive insulin pathway activation. Remarkably, inceptor is upregulated in diabetes and by blocking insulin signaling it might contribute to insulin resistance. What happens if the function of inceptor is inhibited genetically or pharmacologically? The group explored this question by knocking out inceptor in beta cells and by blocking its function using monoclonal antibodies. "The result was exactly what we were hoping for: Insulin signaling and the functional beta cell mass was increased. This makes inceptor a very promising target to treat the root cause of diabetes, the loss and dysfunction of beta cells," says Ansarullah, a study author and diabetes researcher at Helmholtz Zentrum München. "Frederick Banting noted already in his Nobel Prize lecture for the discovery of the life-saving drug insulin a hundred years ago that 'Insulin is not a cure for diabetes, but a treatment of the symptoms'. This has not changed in the last century. Our goal for future research is to leverage on the discovery of inceptor and develop drugs for beta cell regeneration. This could be beneficial for patients with type 1 and 2 diabetes and ultimately lead to diabetes remission," states Lickert. c) Fifth Paragraph: Conclusion (6 points total) i) Give your opinion about how this drug looks back or looks forward related to what is known about it (3pts) ii) Write to your audience something new to think about the drug (2pts) iii) No less than 100 or more than 125 words for the article conclusion section (1pts) Example of Article Conclusion: "A hundred years ago, the discovery of insulin has transformed a deadly illness into a manageable disease. Our discovery of the insulin inhibitory receptor now is another important step to finally get rid of the disease," says Matthias Tschöp, CEO at Helmholtz Zentrum München. "While the COVID-19 pandemic represents an immediate threat we will overcome, we must not forget that diabetes remains one of the biggest and fastest growing killers on our planet. With a series of recent breakthroughs, now including the discovery of inceptor, our Helmholtz Diabetes Center is doubling down on its mission that is a world without diabetes." 6) References (10pts total) a) Utilize the American Medical Association formatting guidelines for the reference section (10pts) b) Make sure you include all the sources you utilized for this assignment The example utilized for this assignment was obtained from: Helmholtz Zentrum München - German Research Center for Environmental Health. "Scientists discover a new promising target for diabetes treatment." ScienceDaily. ScienceDaily, 27 January 2021.
. Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer T h e n e w e ngl a nd j o u r na l o f m e dic i n e n engl j med 380;20 nejm.org May 16, 2019 1929 The authors’ full names, academic de- grees, and affiliations are listed in the Appendix. Address reprint requests to Dr. André at Institut Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif, 94805, France, or at fabrice . andre@ gustaveroussy . fr; or to Dr. Juric at Massachusetts General Hospi- tal Cancer Center, 55 Fruit St., Boston, MA 02114, or at juric . dejan@ mgh . harvard . edu. *A complete list of the investigators in the SOLAR-1 Study Group is provided in the Supplementary Appendix, available at NEJM.org. This article was last updated on May 31, 2019, at NEJM.org. N Engl J Med 2019;380:1929-40. DOI: 10.1056/NEJMoa1813904 Copyright © 2019 Massachusetts Medical Society. BACKGROUND PIK3CA mutations occur in approximately 40% of patients with hormone receptor (HR)– positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer. The PI3Kα-specific inhibitor alpelisib has shown antitumor activity in early studies. METHODS In a randomized, phase 3 trial, we compared alpelisib (at a dose of 300 mg per day) plus fulvestrant (at a dose of 500 mg every 28 days and once on day 15) with placebo plus fulvestrant in patients with HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. Patients were enrolled into two cohorts on the basis of tumor-tissue PIK3CA mutation status. The primary end point was pro- gression-free survival, as assessed by the investigator, in the cohort with PIK3CA-mu- tated cancer; progression-free survival was also analyzed in the cohort without PIK3CA- mutated cancer. Secondary end points included overall response and safety. RESULTS A total of 572 patients underwent randomization, including 341 patients with con- firmed tumor-tissue PIK3CA mutations. In the cohort of patients with PIK3CA-mutated cancer, progression-free survival at a median follow-up of 20 months was 11.0 months (95% confidence interval [CI], 7.5 to 14.5) in the alpelisib–fulvestrant group, as com- pared with 5.7 months (95% CI, 3.7 to 7.4) in the placebo–fulvestrant group (hazard ratio for progression or death, 0.65; 95% CI, 0.50 to 0.85; P<0.001); in the cohort with- out pik3ca-mutated cancer, the hazard ratio was 0.85 (95% ci, 0.58 to 1.25; posterior probability in="" the="" cohort="" with-="" out="" pik3ca-mutated="" cancer,="" the="" hazard="" ratio="" was="" 0.85="" (95%="" ci,="" 0.58="" to="" 1.25;="" posterior="">